Key data reveals for the small players
Praxis, Proqr and Nordic Nanovector are awaiting important data.
SITC 2020 – Oncosec’s investment case sweetens slightly
A Keytruda combo trial of the company’s Tavo shows an improving dataset, as remissions appear to deepen with time.
SITC 2020 – second chances for Merck & Co and Oncosec
Among late-breaking abstracts whose titles have just gone live two mechanisms have a chance to redeem themselves.
Bristol bets on cytokines again
The company’s deal with Dragonfly shows that disappointments have not eliminated interest in cytokine approaches.
SITC 2018 – Nektar’s big reveal falls flat
The company struggles to move the needle at the SITC meeting with an up-to-date cut of its first-line melanoma trial of NKTR-214 and Opdivo.
How many million-dollar drugs can health systems tolerate?
Novartis's $4m price target for AVXS-101 fuels concerns that too many new gene therapies could overburden payers without a hard look at how they are financed.